Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Mallinckrodt to make equity investment in Silence

18 Jul 2019 11:46

RNS Number : 0001G
Silence Therapeutics PLC
18 July 2019
 

 

Mallinckrodt to make an equity invesTment in SILENCE THERAPEUTICS as part of a collaboration TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES

 

- Mallinckrodt Chief Scientific Officer Steven Romano, M.D. joins Silence Board as non-executive Director -

 

LONDON, United Kingdom and STAINES-UPON-THAMES, July 18, 2019 /PRNewswire/ -- Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA[1] interference (RNAi) therapeutics for the treatment of serious diseases and Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announce that, further to the collaboration announced earlier today, Mallinckrodt, acting through a subsidiary company, has agreed to make an equity investment of $5 million in Silence Therapeutics.

 

Mallinckrodt is subscribing for a total of 5,062,167 new ordinary shares at an issue price of 79p per share, representing a 10 percent premium to Silence's 20-day, volume-weighted average price. Application will be made to the London Stock Exchange for the admission of the 5,062,167 new ordinary shares to be subscribed for trading on AIM[2]. It is expected that dealings will commence at 8:00 a.m. BST[3] on 24 July 2019. Immediately following admission, Mallinckrodt's shareholding will represent 6.5 percent of Silence Therapeutics' enlarged, issued share capital which will be 77,285,652 ordinary shares.

As part of this equity investment Mallinckrodt will take a non-executive Director seat on the Silence Board of Directors, and it has been proposed that Steven Romano, M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt fulfill this position. A further announcement, including the disclosures required under Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies, will be made at the time of Dr. Romano's appointment to the Board.

The separate collaboration between Mallinckrodt and Silence Therapeutics announced earlier today will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or silence the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins are known to contribute to the pathogenesis of many diseases, including autoimmune diseases.

 

ABOUT SILENCE

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit https://www.silence-therapeutics.com/.

 

ABOUT MALLINCKRODTMallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

 

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

 

Cautionary Statements Related to Forward-Looking Statements

Mallinckrodt

This release includes forward-looking statements concerning Mallinckrodt's collaboration with Silence, including expectations regarding future research and development plans, potential milestone payments and commercial arrangements and the potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: uncertainties inherent in research and development, including clinical trial results; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

 

Silence

The information contained within this announcement is deemed by the Silence Therapeutics plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

CONTACTS

 

MALLINCKRODT

Investor RelationsDaniel J. Speciale, CPAVice President, Investor Relations and IRO

314-654-3638

daniel.speciale@mnk.com

 

MediaDaniel Yunger

Kekst CNC

212-521-4879

mallinckrodt@kekstcnc.com

 

SILENCE THERAPEUTICS

Dr. David Horn Solomon, Chief Executive Officer

Mr. Iain Ross, Non-Executive Chairman

+44 (0) 20 3457 6900

 

Peel Hunt/LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

+44 (0) 20 7418 8900

 

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gary

silencetherapeutics@consilium-comms.com

+44 (0) 20 3709 5700

 

US IR

Westwicke Partners

Peter Vozzo

Peter.vozzo@westwicke.com

442-213-0505

 

 

 

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2019 Mallinckrodt. 7/19

 

 

[1] Ribonucleic acid

[2] Alternative Investment Market, a sub-market of the London Stock Exchange

[3] British Summer Time

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAEXPFDFNEFF
Date   Source Headline
26th Nov 20217:00 amRNSUpdate on AIM Delisting
25th Nov 20215:30 pmRNSSilence Therapeutics
16th Nov 20217:00 amRNSThird Quarter 2021 Financial Results
11th Nov 20217:00 amRNSSilence to Present at Jefferies London Conference
10th Nov 20217:00 amRNSHolding(s) in Company
5th Nov 20217:00 amRNSNew Key Shareholder
1st Nov 20215:33 pmRNSResult of General Meeting
1st Nov 20214:49 pmRNSTotal Voting Rights
28th Oct 20214:02 pmRNSHolding(s) in Company
21st Oct 20211:30 pmRNSSilence Provides Pipeline Updates at 2021 R&D Day
15th Oct 20217:05 amRNSProposed Cancellation of Trading on AIM
15th Oct 20217:00 amRNSSilence and Hansoh Pharma Announce Collaboration
8th Oct 20217:00 amRNSBlock Listing Return
8th Oct 20217:00 amRNSTotal Voting Rights
7th Oct 20217:00 amRNSSilence Therapeutics to host R&D day
28th Sep 20217:00 amRNSChardan Genetic Medicines Conference Participation
8th Sep 20214:03 pmRNSHolding(s) in Company
8th Sep 20214:00 pmRNSHolding(s) in Company
1st Sep 20217:00 amRNSSilence Appoints Senior VP of BD, AM and NPD.
25th Aug 20217:00 amRNSSilence to Participate in Investor Conferences
12th Aug 20217:00 amRNSSilence Therapeutics Report Half-Year 2021 Results
6th Aug 202112:15 pmRNSHolding(s) in Company
6th Aug 202112:13 pmRNSHolding(s) in Company
5th Aug 20212:57 pmRNSTotal Voting Rights
15th Jul 20217:00 amRNSNotice of half year results
15th Jun 20215:54 pmRNSResults of Annual General Meeting
7th Jun 20217:00 amRNSSilence to present SL124 data at EHA
25th May 20217:00 amRNS$40m Payment from AstraZeneca for Collaboration
19th May 20217:00 amRNSPhase 1 Study in Healthy Volunteers Positive Data
12th May 20217:00 amRNSSilence attends RBC Global Healthcare Conference
7th May 20217:00 amRNSNotice of AGM
4th May 20217:00 amRNSSilence Support International Thalassemia Day
30th Apr 20214:12 pmRNSHolding(s) in Company
29th Apr 20215:58 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSFirst patient dosed in GEMINI II
28th Apr 20217:00 amRNSSilence Achieves Research Milestone Payment
27th Apr 20217:00 amRNSGrant of Employee Options
19th Apr 20217:00 amRNSPurchase of ADS and PDMR Shareholding
15th Apr 20217:00 amRNSPublication in Cardiovascular Research
7th Apr 20217:00 amRNSSilence to Present at Virtual Needham Conference
30th Mar 20216:13 pmRNSSilence Therapeutics Publication of Annual Report
30th Mar 20219:04 amRNSREPLACEMENT Silence Reports Full-year 2020 Results
30th Mar 20217:00 amRNSSilence Reports Full-year 2020 Results
26th Mar 20217:00 amRNSBlock Listing Application
4th Mar 20217:29 amRNSSilence presents at Barclays Healthcare Conference
1st Mar 20217:00 amRNSNotice of Annual Results
26th Feb 20217:00 amRNSSilence & Mallinckrodt Initiate Work on 3rd Target
24th Feb 20213:09 pmRNSHolding(s) in Company
22nd Feb 20217:00 amRNSSilence to Partake in March Investor Conferences
18th Feb 20217:00 amRNSSilence to present at SVB Leerink Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.